Skip to main content

AstraZeneca Pharma India Share Price Gains Over 2%; Signs LOI with Strand Life Sciences for Healthcare Collaboration

Written by: Team Angel OneUpdated on: 17 Nov 2026, 9:09 pm IST
AstraZeneca Pharma India signed a Letter of Intent on Nov 17, 2026, with Reliance's Strand Life Sciences to explore healthcare collaboration in India.
AstraZeneca Pharma India Share Price Gains
Share

AstraZeneca Pharma India Limited announced on November 17, 2026, that it has signed a Letter of Intent (LoI) with Strand Life Sciences Private Limited to explore collaboration opportunities in the Indian healthcare sector.  

The regulatory disclosure was filed with both BSE Limited and the National Stock Exchange of India Limited. 

Key Details of the Letter of Intent 

Under the terms of the Letter of Intent, AstraZeneca Pharma India Limited and Strand Life Sciences Private Limited will evaluate potential areas of partnership across healthcare in India. Strand Life Sciences Private Limited operates as a genomics research and diagnostics company and is a subsidiary of Reliance Industries Limited. 

The company confirmed in its exchange filing that AstraZeneca Pharma India Limited and Strand Life Sciences Private Limited are not related parties. Consequently, the execution of the Letter of Intent does not constitute a related party transaction. 

Corporate Disclosures and Company Background 

Information regarding the partnership has also been shared through AstraZeneca India's official LinkedIn handle and published on the company's corporate website. The regulatory filing was signed by Tanya Sanish, Company Secretary and Compliance Officer of AstraZeneca Pharma India Limited. 

Headquartered in Bengaluru, Karnataka, AstraZeneca Pharma India Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines across key therapeutic areas in India. 

Read More: SC Agrotech Share Price Hits 5% Upper Circuit Post Q2 FY27 Earnings Results; Approves 10:1 Stock Split and 4:5 Bonus Issue! 

AstraZeneca Pharma India Share Price Performance   

As of November 17, 2026, at 2:33 PM, AstraZeneca Pharma India share price on NSE was trading at ₹6,156.00, up by 2.04% from the previous closing price. 

Conclusion 

On November 17, 2026, AstraZeneca Pharma India Limited entered into a non-related party Letter of Intent with Reliance Industries subsidiary Strand Life Sciences Private Limited to explore healthcare collaboration opportunities in India. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. 

Published on: Nov 17, 2026, 3:39 PM IST

Team Angel One

Team Angel One is a group of experienced financial writers that deliver insightful articles on the stock market, IPO, economy, personal finance, commodities and related categories.
Know More
Enjoy Zero Brokerage on Equity Delivery
10 Cr+DOWNLOADS

Enjoy ₹0 Account Opening Charges

Get the link to download the App

Scan this QR code to download the app
Get it on Google PlayDownload on the App Store